Andreasen P A, Nielsen L S, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K
J Biol Chem. 1986 Jun 15;261(17):7644-51.
An approximately 75% pure form of a human Mr approximately 54,000 plasminogen activator inhibitor from conditioned culture fluid of the fibrosarcoma cell line HT-1080 was obtained by a single step of chromatography on concanavalin A-Sepharose. The inhibitor inhibited human urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator, but not plasmin. Rabbit antibodies against this plasminogen activator inhibitor also reacted with a plasminogen activator inhibitor with identical electrophoretic mobility in extracts of human blood platelets, indicating that the HT-1080-inhibitor is of the same type as the inhibitor of blood platelets. As revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by fibrin-agarose zymography, incubation of HT-1080-inhibitor with the active form of human u-PA led to the formation of an equimolar sodium dodecyl sulfate-resistant complex between them; in contrast, no complex formation was observed between the inhibitor and the proenzyme form of human u-PA (pro-u-PA). Likewise, using a column of anti-inhibitor antibodies coupled to Sepharose for removal of excess inhibitor and activator-inhibitor complexes, the potential enzymatic activity of pro-u-PA was found to be unaffected by incubation with inhibitor under conditions in which more than 95% of the active u-PA had formed complex with inhibitor.
通过在伴刀豆球蛋白A - 琼脂糖凝胶上进行一步层析,从纤维肉瘤细胞系HT - 1080的条件培养液中获得了一种纯度约为75%的人源纤溶酶原激活物抑制剂,其分子量约为54,000。该抑制剂可抑制人尿激酶型纤溶酶原激活物(u - PA)和组织型纤溶酶原激活物,但不抑制纤溶酶。针对这种纤溶酶原激活物抑制剂的兔抗体,也能与人血小板提取物中具有相同电泳迁移率的纤溶酶原激活物抑制剂发生反应,这表明HT - 1080抑制剂与血小板抑制剂属于同一类型。十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳后进行纤维蛋白 - 琼脂糖酶谱分析显示,HT - 1080抑制剂与人u - PA的活性形式孵育后,二者之间会形成等摩尔的耐十二烷基硫酸钠复合物;相反,在抑制剂与人u - PA的酶原形式(pro - u - PA)之间未观察到复合物形成。同样,使用偶联了抗抑制剂抗体的琼脂糖凝胶柱去除过量的抑制剂和激活剂 - 抑制剂复合物后,发现在超过95%的活性u - PA已与抑制剂形成复合物的条件下,pro - u - PA的潜在酶活性不受与抑制剂孵育的影响。